Elixir Pharmaceuticals Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cambridge MA United States (1999)
Status: Defunct (2007)

Organization Overview

First Clinical Trial
2007
NCT00519142
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Elixir Medical Corporation | Elixir Pharmaceuticals

Active Ingredients

Drugs in Phase 4 Trials (1)

novolimus (1 trial)

Drugs in Phase 3 Trials (1)

mitiglinide (Glufast) (1 trial)

Drugs in Phase 2 Trials (1)

sirolimus (rapamune) (1 trial)

Drugs in Phase 1 Trials (1)

gemfibrozil (lopid) (1 trial)

Drugs in Other Trials (1)

caffeine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 5